Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1-2 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1-2, 12.2008
- Creator
-
Bánhegyi, D.
- Contributor
-
Katlama, C.
Da Cunha, C.
Schneider, S.
Rachlis, A.
Romanenko, O.
Workman, C.
Vandevoorde, A.
Tomaka, F.
Vangeneugden, T.
Spinosa-Guzman, S.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P22
- URN
-
urn:nbn:de:1111-2016052055159
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bánhegyi, D.
- Katlama, C.
- Da Cunha, C.
- Schneider, S.
- Rachlis, A.
- Romanenko, O.
- Workman, C.
- Vandevoorde, A.
- Tomaka, F.
- Vangeneugden, T.
- Spinosa-Guzman, S.
- SpringerLink (Online service)
Other Objects (12)
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
Delegationsberichte DRV
Einreise DRV
WTZ DRV
Qualifizierungsveranstaltung DRV
Direktverbindungen DRV
DRV, Hilfsfonds
DRV-Delegationsberichte
Direktverbindungen DRV
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
Delegationsberichte DRV
Einreise DRV
WTZ DRV
Qualifizierungsveranstaltung DRV
Direktverbindungen DRV
DRV, Hilfsfonds
DRV-Delegationsberichte
Direktverbindungen DRV
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
Delegationsberichte DRV
Einreise DRV
WTZ DRV
Qualifizierungsveranstaltung DRV
Direktverbindungen DRV
DRV, Hilfsfonds
DRV-Delegationsberichte